πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated β€” grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≀24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β€” use filters for patent-cliff planning.

Page 135 of 173

  1. US 7405286

    Starsβ€”A muscle-specific actin-binding protein

    Expires Mon Jul 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7405041

    Methods for regulating transcription by targeting quadruplex DNA

    Expires Mon Jul 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7399823

    Antimicrobial theta defensins and methods of using same

    Expires Mon Jul 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7399606

    Methods for identifying IΞΊB Kinase (IKK) inhibitors

    Expires Mon Jul 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7399465

    Pharmaceutical compositions for treating arthritis and inflammatory disease

    Expires Mon Jul 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7399750

    Methods for cardiac gene transfer

    Expires Mon Jul 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7396682

    Method for cell adhesion and wound healing

    Expires Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7393855

    2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrimidines as antiviral agents

    Expires Mon Jun 26 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7393994

    Transgenic mouse model for neurodegenerative diseases

    Expires Mon Jun 26 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7393833

    Chimeric proteins with phosphatidylserine binding domains

    Expires Mon Jun 26 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7390646

    Bacterial vectors and methods of use thereof

    Expires Mon Jun 19 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7388071

    Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response

    Expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7387896

    MicroRNA vectors

    Expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7388079

    Delivery of pharmaceutical agents via the human insulin receptor

    Expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7388088

    High affinity human antibodies to tumor antigens

    Expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7388074

    Mutant plasminogen activator-inhibitor type 1 (PAI-1) and uses thereof

    Expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7387881

    Detection and treatment of cancers of the liver

    Expires Mon Jun 12 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7384909

    Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents

    Expires Mon Jun 05 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7381404

    Treatment for dry macular degeneration

    Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7381699

    Reagents and methods for smooth muscle therapies

    Expires Mon May 29 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7378386

    Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives

    Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7378496

    hKCa3/KCNN3 small conductance calcium activated potassium channel: a diagnostic marker and therapeutic target

    Expires Mon May 22 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7375092

    Lunasin peptides

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7374776

    Bone-filling composition for stimulating bone-forming and bone-consolidation comprising calcium sulfate and viscous biopolymers

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7375086

    Modulators of Nod2 signaling

    Expires Mon May 15 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7371364

    Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy

    Expires Mon May 08 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7371571

    Recombinant mycobacteria overexpressing D-alanine ligase gene and uses therefore

    Expires Mon May 08 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7371575

    Process for ex vivo formation of mammalian bone and uses thereof

    Expires Mon May 08 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7371841

    Methods of modulating cold sensory perception

    Expires Mon May 08 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7368275

    In vivo incorporation of unnatural amino acids

    Expires Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7368232

    High-throughput assay for virus entry and drug screening

    Expires Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7368279

    Three dimensional bioengineered smooth muscle tissue and sphincters and methods therefor

    Expires Mon May 01 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7365096

    Methods for selectively inhibiting Janus tyrosine kinase 3 (Jak3)

    Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7365050

    Methods for modulating a drug-related effect or behavior

    Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7365047

    Use of pentagastrin to inhibit gastric acid secretion or as a diuretic

    Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7365175

    Wit 3.0, a novel gene to control soft tissue wound healing

    Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7364726

    Pharmaceutical composition for cancer treatment containing cells that express a membrane cytokine

    Expires Mon Apr 24 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7361332

    Treating tumors using implants comprising combinations of allogeneic cells

    Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7361680

    Indole compounds useful for the treatment of cancer

    Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7361355

    Mutant forms of cholera holotoxin as an adjuvant

    Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7361504

    Culturing Anaplasma

    Expires Mon Apr 17 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7358226

    Ultrasonic concentration of drug delivery capsules

    Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7358222

    Preventing airway mucus production by administration of EGF-R antagonists

    Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7358087

    Compositions and methods for enhancing immune responses mediated by antigen-presenting cells

    Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7358086

    Mammalian two-hybrid system for screening for modulators of the accumulation of metabolic products

    Expires Mon Apr 10 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7354894

    Preventing airway mucus production by administration of EGF-R antagonists

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7354761

    Methods and composition for the production of orthogonal tRNA-aminoacyltRNA synthetase pairs

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7355047

    Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof

    Expires Mon Apr 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources Β· Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.